Company Insight – Page 16 – media

NEJM editorial slams design of GSK’s pivotal trial of 3-in-1 COPD drug Trelegy

GSK is shifting resources towards key therapeutic classes, including respiratory disease.
- Source: fiercepharma.
- 598
- April 24, 2018
Company Insight GSK respiratory disease Trelegy Ellipta
Novartis pads case for new MS blockbuster with disease-progression analysis

Novartis is hoping multiple sclerosis candidate siponimod’s performance in secondary progressive patients can help it secure a blockbuster approval. And now it has more data to put toward that case.
- Source: fiercepharma
- 541
- April 23, 2018
blockbuster Company Insight multiple sclerosis
Merck KGaA, not Pfizer, lands consumer health deal with P&G worth $4.2B

Merck KGaA will hand P&G a consumer business that has grown 6% over the past two years. (Merck KGaA) Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.
- Source: fiercepharma
- 3,304
- April 23, 2018
Company Insight consumer business Merck
BenevolentAI raises $115 million to extend its leading global position in the field of AI enabled drug development

BenevolentAI today announced that it has raised $115 million from new and existing investors at a pre-money valuation of $2 billion in one of the largest funding rounds in the AI pharmaceutical sector.
- Source: benevolent.ai
- 565
- April 20, 2018
AI Company Insight
Rumours Allergan is looking to offload $5bn women’s health unit

According to a piece by Bloomberg, Allergan is looking at options to divest its women’s health unit in a move that could potentially reap about $5 billion.
- Source: pharmafile
- 611
- April 6, 2018
Allergan biosimilar Company Insight
Eli Lilly gets a date with FDA experts for once-rejected rheumatoid arthritis drug baricitinib

Eli Lilly’s one-time blockbuster hopeful baricitinib $LLY is back and on track and ready to run a gamut of outside experts at the FDA.
- Source: Endpts
- 628
- March 23, 2018
baricitinib Company Insight FDA
Forbion Leads $19 Million Series B Financing of Escalier Biosciences to Advance its Topical and Systemic RORt Therapies for Psoriasis and other Autoimmune Diseases

Forbion, one of the leading European life science venture capital firms, today announced that it led the $19 million Series B financing of Escalier Biosciences BV, a privately held biopharmaceutical company based in Nijmegen, The Netherlands. Escalier Biosciences is developing both oral and topical ROR?t drug candidates for psoriasis and other autoimmune diseases.
- Source: biotech-365
- 753
- March 21, 2018
autoimmune Company Insight financing psoriasis
Dova Pharmaceuticals Signs Exclusive Distribution Agreement with Fosun Pharma For Mainland China and Hong Kong

Dova Pharmaceuticals, Inc. (DOVA), a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for rare diseases where there is a high unmet need, entered into an agreement through its wholly owned subsidiary, AkaRx, Inc., granting Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., (Fosun Pharma Industrial), a wholly owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) (SHA:600196) (HKG:02196), the exclusive development and distribution rights of avatrombopag in mainland China and Hong Kong.
- Source: finance.yahoo
- 646
- March 21, 2018
avatrombopag Company Insight rare diseases
Insilico Medicine to launch R&D center and announce new research results in Taiwan ROC

Tuesday, March 20th, 2018, Insilico Medicine, a Baltimore-based artificial intelligence company specializing in drug discovery, biomarker development and aging research announced the launch of Insilico Taiwan, a subsidiary focusing on the development and validation of generative adversarial networks(GANs) and reinforcement learning for medicinal chemistry applications.
- Source: EurekAlert
- 580
- March 21, 2018
AI biomarker Company Insight Researches
DocDoc raises US$5.45mil in Series B funding round

Singapore-based DocDoc, an Asian patient empowerment company, announced on March 19 that it has raised US$5.45 million (RM21.33 million) in their Series B round of funding.
- Source: Digital News Asia
- 608
- March 21, 2018
AI Company Insight healthcare

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.